anti-NLRP1/NALP1 (human) pAb (AL176)
Product Code:
AG-25B-0005
AG-25B-0005
Antibody Clonality:
Polyclonal
Polyclonal
Regulatory Status:
RUO
RUO
Target Species:
Human
Human
Application:
Western Blot (WB)
Western Blot (WB)
Shipping:
-20°C
-20°C
Storage:
-20°C
-20°C
No additional charges, what you see is what you pay! *
| Code | Size | Price |
|---|
| AG-25B-0005-C100 | 100 ug | £300.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- Documents
- References
- Show All
Further Information
Alternate Names/Synonyms:
NACHT-, LRR- and PYD-containing Protein 1; NLRP1; Caspase Recruitment Domain-containing Protein 7; Death Effector Filament-forming Ced-4-like Apoptosis Protein; Nucleotide-binding Domain and Caspase Recruitment Domain
Concentration:
1 mg/ml
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.
Handling Advice:
After opening, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.
Immunogen:
Synthetic peptide corresponding to aa 2-25 (A2GGAWGRLACYLEFLKKEELKEFQ25) at the N-terminus of human NLRP1/NALP1.
Long Description:
Polyclonal Antibody. Recognizes human NLRP1/NALP1. Does not cross-react with mouse NLRP1/NALP1. Source: Rabbit. Applications: WB. Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. NALP1/NLRP1 is able to form cytoplasmic structures termed death effector filaments. It enhances and stimulates apoptosis through activation of different caspase cascades. It is involved in the activation of caspase-1 and caspase-5 as part of the NALP1 inflammasome complex which leads to processing and release of IL1B and IL18. Genetic variations in the NLRP1/NALP1 gene are associated with susceptibility to vitiligo-associated multiple autoimmune disease type 1, an autoimmune disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.
NCBI, Uniprot Number:
Q9C000
Package Type:
Plastic Vial
Product Description:
NALP1/NLRP1 is able to form cytoplasmic structures termed death effector filaments. It enhances and stimulates apoptosis through activation of different caspase cascades. It is involved in the activation of caspase-1 and caspase-5 as part of the NALP1 inflammasome complex which leads to processing and release of IL1B and IL18. Genetic variations in the NLRP1/NALP1 gene are associated with susceptibility to vitiligo-associated multiple autoimmune disease type 1, an autoimmune disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.
Source / Host:
Rabbit
Specificity:
Recognizes human NLRP1/NALP1. Does not cross-react with mouse NLRP1/NALP1.
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.
Documents
References
The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta: F. Martinon, et al.; Mol. Cell. 10, 417 (2002) | Germline NLRP1 Mutations Cause Skin Inflammatory and Cancer Susceptibility Syndromes via Inflammasome Activation: F.L. Zhong, et al.; Cell 167, 187 (2016) | The NLRP1 Inflammasome Pathway Is Silenced in Cutaneous Squamous Cell Carcinoma: J. Sand, et al.; J. Investig. Dermatol. 139, 1788 (2019) | NLRP1 variant M1184V decreases inflammasome activation in the context of DPP9 inhibition and asthma severity: J. Moecking, et al.; J. Allergy Clin. Immunol. 147, 2134 (2021)